Invention Grant
- Patent Title: Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
-
Application No.: US15614434Application Date: 2017-06-05
-
Publication No.: US10245258B2Publication Date: 2019-04-02
- Inventor: Soraya Carrancio , Paul Hollenbach , Antonia Lopez-Girona , Kyle MacBeth , Michael Pourdehnad , Irit Rappley , Gang Lu
- Applicant: Celgene Corporation
- Applicant Address: US NJ Summit
- Assignee: Celgene Corporation
- Current Assignee: Celgene Corporation
- Current Assignee Address: US NJ Summit
- Agency: Jones Day
- Main IPC: A61K31/454
- IPC: A61K31/454 ; A61K9/19 ; A61K9/00

Abstract:
Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
Public/Granted literature
Information query
IPC分类: